Tumor-associated antigen messenger RNA (TAA mRNA) (TAA mRNA)

Tumor antigen RNA refers to messenger RNA (mRNA) sequences that encode specific proteins found predominantly or exclusively on cancer cells, known as tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). In the context of oncology, this RNA is utilized as a therapeutic vaccine modality rather than a traditional biological target; it serves as a genetic template that, when delivered into a patient's cells, instructs them to produce the encoded antigens (Sahin et al., 2014). These antigens are subsequently processed and presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells, such as dendritic cells, to trigger a targeted immune response (Kranz et al., 2016). This process activates cytotoxic T-lymphocytes (CD8+) and helper T-cells (CD4+) to recognize and eliminate tumor cells expressing the corresponding antigens. The use of RNA allows for the simultaneous targeting of multiple antigens and the development of personalized 'neoantigen' vaccines tailored to an individual's specific tumor mutations (Pardi et al., 2018). While this approach is highly versatile and has shown efficacy in clinical trials for melanoma and other solid tumors, challenges remain regarding the stability of the RNA and its efficient delivery to lymphoid tissues (Barbosa et al., 2021). Current research often explores the combination of tumor antigen RNA vaccines with immune checkpoint inhibitors to enhance therapeutic outcomes by overcoming tumor-induced immunosuppression (Sahin et al., 2020).

Other names

Tumor antigen RNATumor antigen mRNACancer vaccine RNATumor-specific antigen RNANeoantigen mRNATotal tumor RNA

Delivery of mRNA encoding tumor antigens into host cells (primarily dendritic cells) where it is translated into proteins that are processed and presented on MHC molecules to stimulate a tumor-specific T-cell response.